Physician profile
Crystal Kim
NPI 1356861645
$2,007.70
in general payments reported to CMS, 2019-2025
21 companies · $457 in 2025
The $457 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.14 · 2020: $91.35 · 2021: $172 · 2022: $455 · 2023: $346 · 2024: $412 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115 · Entertainment: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.10 |
| Entertainment | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $323.14 | 2021-2023 | |
| Alcon Vision LLC | $255.09 | 2022-2025 | Precision 7, Rocklatan, Tryptyr |
| Johnson & Johnson Vision Care, INC. | $231.96 | 2023-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $173.06 | 2022-2025 | Xiidra, Miebo |
| Dompe US, INC. | $149.48 | 2022-2024 | Oxervate |
| Optos, INC. | $100.00 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Sun Pharmaceutical Industries INC. | $94.10 | 2019-2021 | |
| Allergan, INC. | $82.82 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $80.44 | 2022-2023 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $74.42 | 2019-2021 | |
| Harrow Eye, LLC | $63.30 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $62.87 | 2021 | |
| Rxsight INC | $61.12 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Oyster Point Pharma, INC. | $45.33 | 2022-2024 | Tyrvaya |
| Glaukos Corporation | $42.91 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $42.56 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $37.32 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $25.00 | 2024 | |
| Aerie Pharmaceuticals, INC. | $23.00 | 2021 | |
| Shire North American Group INC | $20.98 | 2019 | |
| Thea Pharma INC. | $18.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.